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ABSTRACT
Donor cytotoxic T lymphocytes (CTL) specific for minor histocompatibility antigens (mHA) mediate the
graft-versus-host effect whereas host mHA-specific CTL mediate graft rejection in the setting of major
histocompatibility complex identical allogeneic hematopoietic stem cell transplantation. Development of a
large animal model from which mHA-specific CTL can be isolated would accelerate translation in clinical
studies to improve control of the graft-versus-host effect as well as prevention of graft rejection in sensitized
hosts. The aims of the current study were to isolate mHA-specific CTL from dog leukocyte antigen–identical
littermate nonsensitized recipients before transplantation, from stable mixed hematopoietic chimeras, and
from dogs sensitized to mHA after graft rejection. Donor dendritic cells (DCs) were cultured from bone
marrow–derived CD34 cells and were used to stimulate recipient T lymphocytes on days 1, 10, and 20 of CTL
culture. We reliably generated and expanded mHA-specific CTL ex vivo from sensitized dogs that were given
a donor-specific blood transfusion to boost immune recall after graft rejection after a nonmyeloablative
transplantation. The mHA-specific cytotoxicity measured by 51Cr release assay was enriched from less than 5%
in the starting population of sensitized peripheral blood mononuclear cells to a median of 63% after 4 weeks
in CTL culture. The expanded mHA-specific CTLs were not tissue-specific: hematopoietic cells, fibroblast,
and stromal cell lines were lysed in an mHA-specific manner. Allogeneic DCs, but not peripheral blood
mononuclear cells, were necessary for stimulating ex vivo expansion of mHA-specific CTL. We were unable to
generate mHA-specific CTL from nonsensitized dogs before transplantation, from previously sensitized dogs
but without recent recall immunization, or from stable mixed hematopoietic chimeras. We conclude that
after recent in vivo sensitization, large-scale ex vivo expansion of mHA-specific CTL was feasible using
allogeneic DCs.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
After major histocompatibility complex (MHC)–
identical hematopoietic stem cell transplantation
(HSCT), donor-derived, minor histocompatibility an-
tigen (mHA)–speciﬁc cytotoxic T lymphocytes (CTL)
mediate graft-versus-host disease (GVHD) and the
graft-versus-leukemia (GVL) effect whereas host-de-
rived mHA-speciﬁc CTLs mediate graft rejection [1].
In the nonmyeloablative HSCT setting, the role of
mHA-speciﬁc CTLs is particularly important because
the intensity of the conditioning regimen is signiﬁ-
cantly reduced and postgrafting pharmacological im-
munosuppression is intensiﬁed to control both
GVHD and graft rejection [2,3]. In the canine HSCT
model, donor T cells, including mHA-speciﬁc CTLs,
are necessary for sustained engraftment [4] and con-
version to complete donor chimerism [5]. Likewise,
we hypothesized that host-derived mHA-speciﬁc
CTL mediated graft rejection if the host was sensi-
tized previously to donor antigens [6] or if the condi-
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tioning regimen or postgrafting immunosuppression
was insufﬁcient [2,7-9]. Development of a large ani-
mal model for studying mHA-speciﬁc CTLs could
accelerate translation in clinical studies to further de-
crease the intensity of conditioning regimen while
enhancing the GVL effect and preventing GVHD or
preventing graft rejection in sensitized hosts.
Previously, it was difﬁcult to reliably generate ca-
nine mHA-speciﬁc T cells ex vivo, and expansion of
CTLs was very limited [10]. We used the recently
isolated and characterized canine dendritic cells (DCs)
[11] to stimulate the ex vivo expansion of mHA-spe-
ciﬁc CTL from dog leukocyte antigen (DLA)–identi-
cal littermates. We asked if mHA-speciﬁc CTLs could
be isolated from healthy dogs before transplantation,
from stable mixed hematopoietic chimeras, and from
dogs sensitized to mHAs after graft rejection.
MATERIALS AND METHODS
Experimental Animals
Litters of random-bred dogs weighing from 8.0 to
14.7 kg and 6 to 12 months old were raised at the Fred
Hutchinson Cancer Research Center or obtained
from commercial kennels licensed by the United
States Department of Agriculture. Research was con-
ducted per the principles in the Guide for Laboratory
Animal Facilities and Care (National Academy of Sci-
ences, National Research Council). The Institutional
Animal Care and Use Committee of the Fred
Hutchinson Cancer Research Center approved the
research protocol. Kennels are certiﬁed with the
American Association for Accreditation of Laboratory
Animal Care. During the study, dogs were examined
at least twice daily. DLA-identical littermate pairs
were chosen on the basis of identical highly polymor-
phic MHC class I and class II microsatellite markers
[12]. Speciﬁc DLA DRB1 allelic identity was deter-
mined using direct sequencing [13]. Refer to Table 1
for summary of the experimental dogs used in this
study.
Sensitization to mHAs
Treatment Group A. Pretransplantation sensitiza-
tion to mHAs was performed in 4 bone marrow re-
cipient dogs. Each dog was given 3 serial nonirradi-
ated whole blood (heparinized) transfusions (50 mL
each) infused on days 24, 17, and 10 from the
respective DLA-identical littermate donor. On day 0,
sensitized recipients were given 2 Gy of total body
irradiation (TBI) at 0.07 Gy/min from a high-energy
linear accelerator source (Varian CLINAC 4, Palo
Alto, CA) followed by transplantation of bone marrow
[14] from the DLA-identical littermate. Dogs received
combined mycophenolate mofetil (MMF), 10 mg/kg
subcutaneously, twice daily, and cyclosporine (CSP),
15 mg/kg orally, twice daily, for 4 and 5 weeks after
transplantation, respectively. All 4 bone marrow re-
cipients were shown to be sensitized to donor mHAs
with immediate rejection of their donor grafts with
complete reconstitution of autologous hematopoiesis,
conﬁrmed using microsatellite marker studies [15].
Six to 8 months after marrow transplantation, the
4 previously sensitized dogs received a transfusion of
50 mL of nonirradiated whole blood from the rejected
DLA-identical marrow donor to boost the immune
recall to mHAs. Ten days later, 4  107 of peripheral
blood mononuclear cells (PBMCs) were isolated using
Ficoll-Hypaque (1.074 speciﬁc gravity) density gradi-
ent centrifugation of 40 to 60 mL of heparinized
blood from the mHA-sensitized dogs. Treatment
group A is hereafter also referred to as previously
sensitized and given recall immunization.
To determine if recall immunization or prior in vivo
Table 1. Experimental Treatment Groups* and DLA-Identical Littermate Pairs for Isolation of mHA-Speciﬁc CTLs
Treatment Group A Treatment Group B Treatment Group C Treatment Group D




to donor mHA owing to
graft rejection after
nonmyeloablative
HSCT in prior 6-8 mo
• Day 10 recall
immunization
• Previously sensitized to
donor mHA owing to
graft rejection after
nonmyeloablative
HSCT in prior 6-8 mo
• No recall immunization
• Nonsensitized PBMCs obtained
before scheduled
transplantation
• Stable mixed hematopoietic
chimera 8-22 mo after
nonmyeloablative HSCT
Donor 3 recipient: DLA-identical littermate pairs for nonmyeloablative HSCT
E614 3 E608 E699 3 E692 E212 3 E214 E874 3 E873
E768 3 E765 G006 3 G005 E991 3 E988 E942 3 E941
E892 3 E894 E972 3 E970
E903 3 E902 E991 3 E988




sensitization to mHAs was necessary for generating
mHA-speciﬁc CTL, 2 control groups were studied.
Treatment Group B. PBMCs were obtained from 2
dogs, G005 and E692, that 6 and 8 months previously,
respectively, had rejected a DLA-identical littermate
bone marrow graft after 1 Gy of TBI conditioning.
G005 had received CSP/MMF and E692 received
CSP only as posttransplantation immunosuppression.
PBMCs for in vitro studies were obtained from these
dogs without preceding recall immunization with do-
nor-speciﬁc blood transfusion. Because of the prior
graft rejection, these dogs were sensitized previously
to donor mHAs, similar to group A. They served as a
control for group A to determine if boosting immune
recall to mHAs after graft rejection was necessary for
ex vivo generation of mHA-speciﬁc CTL. Group B
also is referred to as previously sensitized without
recall immunization.
Treatment Group C. PBMC were obtained from 2
dogs before bone marrow transplantation that were
not sensitized to their respective DLA-identical litter-
mate. For each dog pair studied, 1 to 3 independent
experiments to generate mHA-speciﬁc CTLs ex vivo
were performed.
Establishment of Mixed Hematopoietic Chimerism
Treatment Group D. Stable mixed donor/host he-
matopoietic chimerism was established in 4 dogs with
a nonmyeloablative regimen of TBI, DLA-identical
marrow, and a brief course of postgrafting CSP/MMF
immunosuppression as previously described [2,16].
The bone marrow recipients, E873, E941, E970, and
E988, had 15%, 55%, 80%, and 40% stable donor
chimerism in the PBMC fraction, respectively, which
remained unchanged during the 20-week period be-
fore obtaining blood for the mHA-CTL studies.
PBMCs obtained from these 4 mixed chimeras at 8 to
22 months after transplantation were evaluated for the
ability to generate mHA-speciﬁc CTLs against DCs
obtained from the respective DLA-identical littermate
bone marrow donor.
Generation of DCs
DCs from the respective bone marrow donor were
used to stimulate and expand mHA-speciﬁc CTLs
cultured from the sensitized (treatment group A and
B), nonsensitized (treatment group C), or mixed chi-
meric (treatment group D) dog PBMCs. DCs were
cultured from bone marrow CD34 cells with modi-
ﬁcation of the previously described method [11].
Brieﬂy, bone marrow was aspirated from the femora
of anesthetized dogs [14], hemolyzed, and the pelleted
cells were resuspended in Hank’s balanced salt solu-
tion with 2% heat-inactivated horse serum at 1 
108/mL. Cells were incubated with canine anti-CD34
monoclonal antibody 2E9 [17] 40 g/mL for 30
minutes at 4° C and washed. After incubation with
100 L/mL IgG1-isotype-speciﬁc immunomagnetic
beads (Miltenyi Biotech, Auburn, CA) for 20 minutes,
cells were loaded onto an AutoMACS cell separation
device (Miltenyi Biotech) according to the manufac-
turer’s instructions for positive cell selection. An ali-
quot of the adsorbed cell fraction was reserved for
ﬂow cytometry analysis to determine CD34 cell pu-
rity [18]. The CD34 enriched cells were seeded at
0.5 106/well in 24 well plates (Costar, Corning, NY)
for 14 days in Iscove’s medium containing 10% autol-
ogous heat inactivated dog serum, 5 ng/mL granulo-
cyte macrophage colony-stimulating factor (Immu-
nex, Seattle, WA), 200 ng/mL ﬂt3 ligand, and 10
ng/mL tumor necrosis factor– (TNF) (R&D Sys-
tems, Minneapolis, MN). The medium was changed
every other day beginning on day 5 of culture, and 1
to 1.5 mL of fresh medium with cytokines was added.
The cells were split 1:2 after 7 days in culture. The
DCs were washed and irradiated (22 Gy, 137Cs source)
before use as stimulator cells.
Ex Vivo Expansion of mHA-Specific CTLs
Responder PBMCs were cultured (2  106/well,
Costar) with the respective DLA-identical littermate
DCs on day 1 and restimulated with DCs on day 10
and 20 of culture at a 10:1 ratio, respectively. Inter-
leukin-2 (10 IU/mL, Chiron, Emeryville, CA) was
added on days 12 and 22. When PBMCs instead of
DCs were used as irradiated stimulators, culture con-
ditions were the same except the responder to stimu-
lator ratio was 1:1. Cells were grown in Iscove’s me-
dium containing 10% heat inactivated serum of the
dog from which the stimulator DCs (or PBMCs) were
obtained, 2 mmol/L of L-glutamine, 1 mmol/L of
nonessential amino acids, 1 mmol/L of sodium pyru-
vate, 50 IU/mL of penicillin, and 50 mg/mL of strep-
tomycin. Before each restimulation, mHA-speciﬁc
CTL activity was assessed using the following: (1)
proliferation assay (3[H]TdR incorporation), (2) spe-
ciﬁc cytotoxicity assay (51chromium release), (3) im-
munophenotyping studies, and (4) measurement of cell
expansion (cell count with trypan blue dye exclusion).
Cell Proliferation Assay
In 6 to 12 replicate wells in 96-microwell U-
bottom tissue culture plates (Costar), 1  105 re-
sponder PBMCs were cultured with -irradiated (22
Gy, 137Cs source) stimulator cells, either DCs (2 
104/well) or PBMCs (1  105/well). Responder cells
for secondary stimulation were obtained from bulk
cultures at day 10 after primary stimulation without
the subsequent addition of interleukin-2. Cells were
pulsed for 18 hours with tritiated thymidine
(3[H]TdR, 0.037 mBq/well, Amersham, St. Louis,
MO) at 4, 5, and 6 days after primary stimulation or at
3, 4, and 5 days after secondary stimulation, and then
harvested (Packard, Meridien, CT). Counts per
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minute (CPM) were measured using -scintillation
counter (Packard).
Analysis of Cytotoxicity
Cytotoxicity of mHA-speciﬁc T cells was mea-
sured using a standard 51Cr release assay. Brieﬂy, 1 
106 target cells, either 1  106 concanavalin-A stim-
ulated dog PBMCs (con-A blasts) or CD34-derived
DCs, were incubated with 1.85 mBq 51Cr (Dupont,
Boston, MA) for 1 hour at 37°C. The target cells were
washed 5 times and then incubated for 4 hours with
effector CTLs at various effector to target ratios in
triplicate at 200 L/well. The percentage of speciﬁc
lysis was calculated according to the standard formula
[19]. Mean values are based on 3 to 4 replicates 95%
conﬁdence interval.
Alloreactivity to Bone Marrow Stroma
and Fibroblasts
In preparation for assessing mHA-speciﬁc reactiv-
ity to stroma and ﬁbroblasts, stromal cells were ob-
tained using marrow aspirate and placed in long-term
marrow culture with RPMI, 12.5% horse serum,
12.5% dog serum, 106 mol/L hydrocortisone, 0.1%
-mercaptoethanol, plus the supplements used in
CTL medium. Bone marrow-derived ﬁbroblasts were
cultured in Iscove’s medium containing 10% fetal
bovine serum for 5 to 6 weeks before replating for the
cytotoxicity assay [20]. The mHA-speciﬁc CTLs cul-
tured for 28 days from sensitized dogs with recall
immunization (treatment group A) were added (1 
105, 0.5  105, 0.25  105 cells/well) to a 96-well
ﬂat-bottom plate (Costar) containing either conﬂuent
DLA-identical littermate, autologous, or third party
stromal cells or ﬁbroblasts previously pulsed for 1
hour with 0.037 mBq 51Cr per well and extensively
washed. After 4 hours, culture supernatants were har-
vested, CPM were measured using -counter, and
percentage of cytotoxicity was calculated using the
standard formula: ([experimental CPM]-[spontaneous
CPM]) 	 ([maximum CPM]-[spontaneous CPM]) 
100. Signiﬁcant lysis of stroma or ﬁbroblasts was de-
ﬁned as 1.5  control lysis [21]. Five to 10 replicate
wells per assay were performed.
Monoclonal Antibodies
The following canine monoclonal antibodies
(MoAbs) speciﬁc for cell surface antigens were used:
CD34 (2E9, immunoglobulin [Ig]G1) [18], HLA-DR
(cH81.98, IgG2a, provided by Michel Pierres, Mar-
seilles, France) [22], and CD14 (Tuk4, IgG2a, Dako,
Carpenteria, CA). In addition, CD3
 (CA17.6F9,
IgG2b), CD4 (CA13.1E4, IgG1), CD8 (CA9.JD3,
IgG2a), CD1c (CA13.9H11, IgG1), and CD11c
(CA11.6A1, IgG1) canine-speciﬁc MoAbs were pro-
vided by Peter Moore, University of California Davis
[5,11]. Biotinylated and ﬂuorescein isothiocyanate–
labeled negative murine isotype control MoAbs were
purchased from Dako.
Flow Cytometric Analysis of Cells
Freshly isolated and cultured cells were analyzed
using ﬂow cytometry for expression of cell surface
antigens using the ﬂuorescein isothiocyanate–conju-
gated or biotinylated MoAbs described above at 4
g/mL. Cell incubations and washes were completed
at 4°C in Hank’s balanced salt solution with 2% heat-
inactivated horse serum followed by secondary stain-
ing with streptavidin-phycoerythrin. Propidium io-
dide (1 g/mL) was added to exclude dead cells.
Analysis was performed on a FACScalibur ﬂow cy-
tometer (Beckton Dickinson, San Jose, CA) withWin-
List software (Verity Software House, Topsham, ME).
RESULTS
DCs
In the experiments using DCs, the initial CD34
purity ranged from 46% to 89% (median, 55%). After
14 days of culture in DC medium, 80% of cells had
the classic DC veiled morphology. The DC pheno-
type was conﬁrmed using ﬂow cytometry with 90%
MHC class II bright expression, 85% to 99.5%
CD14-, 90% CD1c, and 32% to 55% CD11c
expression. Cultured DCs previously were shown to
have 23- to 40-fold increased allostimulatory activity
compared with PBMCs in primary mixed lymphocyte
reaction assays in the MHC-mismatched setting [11].
DCs versus PBMCs as Stimulators of
mHA-Specific CTLs
We compared DCs with PBMCs as irradiated
stimulator cells for generating mHA-speciﬁc CTLs
from dogs previously sensitized and given recall im-
munization (treatment group A). Figure 1 shows DCs
were superior to PBMCs as stimulators for generating
mHA-speciﬁc proliferation after primary and second-
ary stimulation. The difference between DC and
PBMC allostimulatory activity was most apparent af-
ter secondary stimulation when DCs generated a 13-
fold increase in proliferation over PBMC at day 14 in
culture.
mHA-Specific CTLs Isolated from Sensitized Dogs
Donor DCs were added as stimulator cells to re-
cipient PBMCs on days 1, 10, and 20 of culture. After
28 days in culture, CTLs derived from dogs previously
sensitized and given recall immunization (treatment
group A) showed a high level of mHA-speciﬁc lysis.
After the third DC stimulation, there was 32% to 78%
(median, 63%) speciﬁc CTL lysis of the respective
DLA-identical littermate DC targets. There was no
signiﬁcant difference in assessment of mHA-speciﬁc
mHA-Specific T Cells
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cytotoxicity with DCs as targets (Figure 2A) compared
with con A blasts (Figure 2B). Freshly isolated PBMCs
from these sensitized dogs had insigniﬁcant lysis of
targets (5%). Control experiments (Figure 2C)
showed the mHA-speciﬁc CTLs had consistently in-
signiﬁcant lysis of autologous target cells and a panel
of 3 to 4 DLA-nonidentical, unrelated third party
target cells. This conﬁrmed the observation that the
cytolytic activity was speciﬁc for mHAs. The mHA-
speciﬁc CTL activity measured using the percentage
of speciﬁc lysis was enriched after successive DC stim-
ulation of sensitized PBMCs (Figure 2D). There was
insigniﬁcant enrichment of mHA-speciﬁc CTL activ-
ity when DLA-identical PBMCs were used as stimu-
lators (Figure 2E). This showed that DCs were nec-
essary for ex vivo expansion of mHA-speciﬁc CTLs.
Requirement for In Vivo Sensitization and Recall
Immunization to mHA
In vivo sensitization and recent recall immuniza-
tion to mHA was necessary for efﬁciently generating
mHA-speciﬁc CTLs ex vivo. PBMCs from nonsensi-
tized dogs (treatment group C) cultured under the
same conditions used for expansion of mHA-speciﬁc
CTLs from sensitized dogs did not effectively lyse the
respective DLA-identical littermate DCs or con A
blasts. In 4 independent experiments, cells from non-
sensitized dogs assayed after third DC stimulation had
15% mHA-speciﬁc lysis at a 20:1 effector to target
ratio (Figure 2F).
We asked whether boosting immune recall to
mHAs was necessary for ex vivo expansion of mHA-
speciﬁc CTLs from previously sensitized dogs. PBMCs
were obtained from 2 dogs (treatment group B) that 6
to 8 months previously had rejected DLA-identical
bone marrow grafts after a nonmyeloablative condi-
tioning regimen and, thus, were previously sensitized.
In contrast to the recall immunized dogs shown in
Figure 2A to 2D, this group of dogs did not receive
transfusion of donor-speciﬁc blood 10 days before
collection of PBMCs and start of culture. DCs from
the respective DLA-identical donor were used as de-
scribed above to stimulate mHA-speciﬁc CTLs. As
shown in Figure 2G, there was no evidence of mHA-
speciﬁc cytotoxicity of cultured cells.
mHA-Specific CTLs Were Not Isolated from
Mixed Hematopoietic Chimeras
Mixed chimerism was established after a non-
myeloablative TBI-based conditioning regimen and
a DLA-identical littermate marrow grafting [2,16].
PBMCs were obtained from 4 stable mixed hemato-
poietic chimeras 8 to 22 months after transplantation.
Stimulatory DCs were obtained from the respective
bone marrow donor and, separately, from DLA-non-
identical, unrelated dogs to stimulate the PBMCs ex
vivo. After repeat in vitro stimulation with respective
DLA-identical DCs, there was 0 to 8% (median, 2%)
mHA-speciﬁc lysis at a 20:1 effector to target ratio
(Figure 2H). The lack of response to DLA-identical
DCs was not due to anergy or poor immune recon-
stitution. After 2 serial stimulations of PBMCs from
mixed chimeras with DLA-nonidentical DCs, there
was 28% to 45% allospeciﬁc lysis (data not shown).
mHA-Specific CTLs Lyse Bone Marrow Stroma
and Fibroblasts
After 3 serial DC stimulations during the 28 days
in culture, the mHA-speciﬁc CTLs from dogs previ-
ously sensitized and given recall immunization (treat-
ment group A, Figure 2A to 2C) were assessed for
ability to lyse stroma and ﬁbroblasts. CTLs were
added to DLA-identical littermate, autologous, and
third party stroma in increasing amounts and assessed
for cytotoxicity. There was 69% and 74% lysis of DLA-
identical littermate donor stroma and ﬁbroblast cells,
respectively, with insigniﬁcant lysis of autologous or
third party stroma or ﬁbroblast cells (Figure 3).
Immunophenotype of mHA-Specific CTLs
After stimulation with DCs and 28 days in culture,
the mHA-speciﬁc CTLs obtained from dogs previ-
ously sensitized and given recall immunization (treat-
ment group A, Figure 2A to 2C) were 96% to 99%
CD3, 70% to 85% CD8, and 16% to 31% CD4.
Figure 4A and 4B show a representative histogram of
Figure 1. Proliferation of mHA-speciﬁc CTLs was enhanced with
allogeneic DCs as stimulators. Representative results (n  6) from
a single dog pair are shown. In 6 to 12 replicate wells in 96-well
plates, 1  105 responder PBMCs from dog E608 (treatment group
A, previously sensitized and given recall immunization from dog
E614) were cultured with irradiated E614 stimulator cells, either
DCs (solid bars, 2  104/well) or PBMCs (thatched bars, 1 
105/well). Cells were pulsed for 18 hours with 3[H]TdR at 4, 5, and
6 days after primary stimulation, or at 3, 4, and 5 days after
secondary stimulation, and then harvested. Results are shown as
CPM  standard error.
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the mHA-speciﬁc CTL immunophenotype (6 inde-
pendent experiments).
Ex Vivo Expansion of mHA-Specific CTLs
Based on the starting number of PBMCs from
dogs previously sensitized and given recall immuniza-
tion (treatment group A) that were added to the allo-
stimulatory DLA-identical DC culture on day 1, there
was an initial decrease in the absolute number of
viable cells after the ﬁrst and second DC stimulation
(Figure 4C). This was followed by a 2- to 6- fold
expansion of alloreactive cells after the third DC stim-
ulation. In contrast, there was a steady decrease in the
number of viable T cells when DLA-identical PBMCs
were used for stimulation of sensitized PBMCs or
when PBMCs from nonsensitized dogs (treatment
group C) were stimulated with DCs. In the latter 2
experimental conditions, the ﬁnal cell contents in cul-
ture were 6% to 8% of the starting PBMCs. These
results support the observation that DCs were supe-
rior to PBMCs as stimulators for expanding mHA-
speciﬁc CTLs and that PBMCs from dogs previously
sensitized and given recall immunization generated
mHA-speciﬁc CTLs more efﬁciently.
DISCUSSION
In this study, mHA-speciﬁc CTL were reliably
generated and expanded from PBMCs obtained from
dogs previously sensitized in vivo and recently rechal-
lenged through transfusion of donor-speciﬁc whole
blood. Cytotoxicity was increased from 5% in the
starting population of sensitized PBMCs to a median
of 63% after 4 weeks in culture. DLA-identical litter-
mate DCs were necessary for optimal ex vivo prolif-
eration and expansion of mHA-speciﬁc CTLs. Under
ex vivo culture conditions including 3 serial allogeneic
DC stimulations, there was a progressive increase of
mHA-speciﬁc CTL activity. The CD34-derived do-
nor DCs used in these studies were at least 10-fold
Figure 2. mHA-speciﬁc cytotoxic activity of cultured CTLs and freshly isolated PBMCs measured by 51Cr release assay. Assay targets were
DCs or con-A blasts from the respective DLA-identical stimulator dog with autologous con-A blasts and a panel of third party con-A blasts
as controls. A to C depict the median speciﬁc lysis standard error of 6 separate experiments from all 4r dogs in treatment group A (previously
sensitized dogs given recall immunization). Lysis of (A) respective DLA-identical donor DC targets, (B) respective DLA-identical donor con-A
blasts, and (C) a panel of third party and autologous con-A blasts. (D) Representative example of enhanced mHA-speciﬁc activity after the ﬁrst,
second, and third DC stimulation. CTLs were cultured from PBMCs of sensitized dog E608 (treatment group A), with assessment of the
percentage of speciﬁc lysis of the DLA-identical littermate E614 DC targets. (E) Representative example of poor ex vivo enrichment for speciﬁc
lysis of mHA targets after serial stimulation with PBMCs. Cells from dog E608 (treatment group A) were serially stimulated with E614 PBMCs
and assessed for lysis of E614 and E608 targets. (F) Minimal lysis of DLA-identical targets with cells obtained from nonsensitized dogs
(treatment group C). (G) No evidence of enrichment of mHA-speciﬁc CTL lytic activity from T lymphocytes of dogs in treatment group B.
Two recipients were previously sensitized to donor mHA but not given a recent donor-speciﬁc blood transfusion. After serial in vitro
stimulation of PBMCs with donor DCs, there was no lysis of the respective DLA-identical targets. (H) Mixed chimeras (treatment group D)
did not generate mHA-speciﬁc CTLs in vitro. Shown are results of median speciﬁc lysis  standard error from 4 mixed chimeras serially
stimulated with DLA-identical donor DCs.
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more efﬁcient at expansion of allospeciﬁc CTL com-
pared with the more cumbersome method of using
DC-enriched PBMCs [10] based on the number of
DCs needed to generate mHA-speciﬁc CTLs. Our
results are consistent with the notion that DCs pro-
vide optimal presentation of mHAs ex vivo to stimu-
late CTL responses. Without prior in vivo sensitiza-
tion of dogs, we were unable to generate mHA-
speciﬁc CTLs using the current method of T-cell
expansion. In addition, our results show that a donor-
speciﬁc whole blood transfusion to boost the immune
recall to mHAs was necessary to isolate mHA-speciﬁc
CTLs from previously sensitized dogs. This may have
been because of the low frequency of mHA-speciﬁc T
cells circulating in the blood of nonsensitized dogs or
animals sensitized in the more distant past.
Although hematopoietic cells were used to sensi-
tize recipients in this study, the mHA-speciﬁc CTLs
isolated from dogs were not tissue-speciﬁc. Both mar-
row stroma and ﬁbroblasts were lysed in an mHA-
speciﬁc manner. These results are consistent with pre-
vious ﬁndings in which stromal cells became targets of
a GVH reaction in patients with poor marrow func-
tion after transplantation [23]. In addition, the results
support the suggestion that immunogenic mHAs in-
volved in marrow graft rejection can be shared among
nonhematopoietic tissues.
We were unable to isolate mHA-speciﬁc CTLs
from mixed chimeric dogs. Stable mixed hematopoi-
etic chimerism after a nonmyeloablative preparative
regimen in the dog reﬂects a state of donor-host
immune tolerance. In this setting, skin and kidney
grafts from the bone marrow donor are accepted in-
deﬁnitely in the mixed chimera without further im-
munosuppression [24]. We have hypothesized that an
active suppressor cell mechanism is responsible for
maintaining the stability of mixed chimerism [5]. Our
results suggest that alloreactive lymphocytes are not
circulating in the mixed chimeras at high frequency
despite the persistence of potentially allostimulatory
mHAs. Whereas further studies are needed to reveal
the mechanism of stable mixed chimerism, our results
indicate that the tolerance mechanism in mixed chi-
meras blocks the emergence of alloreactive lympho-
cytes.
Although we report that mHA-speciﬁc CTLs
were successfully isolated from dogs that had previ-
ously rejected DLA-identical littermate marrow
grafts, the ex vivo expansion of mHA-speciﬁc CTLs is
also feasible from dogs that have been sensitized by
nonirradiated blood transfusions or serial skin grafts
from DLA-identical littermates (unpublished results).
These ﬁndings are potentially applicable to other ex-
perimental settings, such as the generation of mHA-
speciﬁc T cells for adoptive immunotherapy. Ex vivo
expansion of mHA-speciﬁc human CTLs is feasible,
and preliminary clinical experience has been reported
[25,26]. However, a large animal model of mHA-
speciﬁc CTLs would be useful to accelerate clinical
progress. Our results are particularly relevant to this
aim.
There are more than 50 mHAs identiﬁed in the
mouse and many that have been identiﬁed in humans,
although several hundred minor antigens are postu-
lated to exist in humans [27]. Although the mHAs
responsible for the CTL expansion in this report were
not identiﬁed, these results show a robust, general
method for expanding mHA-speciﬁc CTLs in dogs
that may be applied to any MHC-matched setting.
In summary, we describe the ex vivo isolation of
mHA-speciﬁc CTLs from dogs previously sensitized
and given recall immunization using DCs. Such
mHA-speciﬁc CTLs could not be ex vivo expanded
from nonsensitized dogs or mixed hematopoietic chi-
meras. The current results deﬁne a model system to
permit the large-scale expansion of mHA-speciﬁc
Figure 3. mHA-speciﬁc CTLs lysed bone marrow stroma and ﬁbrolasts. CTLs from dogs sensitized and given recall immunization (treatment
group A, Figure 3A to 3C) efﬁciently lysed bone marrow stroma and ﬁbroblasts of the DLA-identical donor (solid line), but not of autologous
or third party bone marrow stroma and ﬁbroblasts (dashed line). The number of effector CTLs added per well 103 is indicated on the x-axis.
Shown are results of median speciﬁc lysis  standard error from the 3 dogs studied.
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CTLs for in vivo studies in the dog model of HSCT.
Because mHA-speciﬁc CTLs mediate graft rejection,
isolation of these cells will facilitate development of
new strategies to overcome resistance to engraftment
in sensitized hosts. In addition, when the hematopoi-
etic stem cell donor is sensitized to the recipient
mHAs, the GVH activity of mHA-speciﬁc CTLs
could be used to convert stable mixed chimerism to
complete donor chimerism after nonmyeloablative
HSCT. Conversion of mixed to complete donor he-
matopoietic chimerism is a surrogate for testing the
GVL effect in a robust, preclinical large animal
model. In vivo studies of mHA-speciﬁc CTLs would
permit the testing of novel methods to control the risk
of development of GVHD [28]. For example, we have
previously shown that retroviral transduction with the
herpes simplex virus thymidine kinase gene can confer
ganciclovir sensitivity to allospeciﬁc CTLs [19]. In
future studies, mHA-speciﬁc CTLs genetically mod-
iﬁed with a suicide gene could be used to enhance the
control and safety of the GVH effect after nonmy-
eloablative allogeneic HSCT.
ACKNOWLEDGMENTS
Supported in part by grants DK02753, DK42716,
HL63457, CA78902, and CA15704 awarded by the
National Institutes of Health, Department of Health
and Human Services, Bethesda, MD, and a grant from
the G&P Foundation for Cancer Research, New
York, NY. M.-T. L. received support from the Lady
Tata Memorial Trust, London, United Kingdom.
The authors are grateful to the technicians of the
Shared Canine Resource and the Hematology and
Transplantation Biology Laboratories for their tech-
nical assistance. We thank Benjamin Weigler, DVM,
PhD, and Michelle Spector, DVM, who provided vet-
erinary support. We are very grateful to Helen Craw-
ford, Bonnie Larson, Sue Carbonneau, and Karen
Carbonneau for their outstanding secretarial support.
The ft3 ligand was a gift from Immunex Corporation.
REFERENCES
1. Martin PJ. Overview of marrow transplantation immunology.
In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell
Transplantation. Boston: Blackwell Science; 1999:19 -27.
2. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic
chimerism in DLA-identical littermate dogs given sublethal
total body irradiation before and pharmacological immunosup-
pression after marrow transplantation. Blood. 1997;89:3048-
3054.
3. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hemato-
poietic cell transplantation in older patients with hematologic
malignancies: replacing high-dose cytotoxic therapy with graft-
versus-tumor effects. Blood. 2001;97:3390-3400.
4. Zaucha JM, Zellmer E, Georges G, et al. G-CSF-mobilized
peripheral blood mononuclear cells added to marrow facilitates
Figure 4. Immunophenotype and expansion of mHA-speciﬁc CTLs.
(A and B) Representative example (n  6) of the phenotype of mHA-
speciﬁc CTLs on day 28 of culture (8 days after third DC stimulation)
isolated from dogs in treatment group A. Cells were 97% CD3, 80%
CD8, and 24% CD4. (C) Total viable cell number was measured
using trypan blue dye exclusion at the beginning of culture and after
ﬁrst, second, and third DC stimulation (days 9, 19, and 28, respec-
tively). Shown are results of 6 separate experiments that generated
mHA-speciﬁc CTLs from 4 dogs previously sensitized and given recall
immunization with the median cell number  standard error normal-
ized to the starting number of responder PBMCs. Despite the decrease
in absolute cell number at the end of 28 days in culture, there was sub-
stantial enrichment of the mHA-speciﬁc cytotoxicity of the cultured
cells compared with the starting population of freshly isolated PBMCs.
mHA-Specific T Cells
241BB&MT
engraftment in nonmyeloablated canine recipients: CD3 cells
are required. Biol Blood Marrow Transplant. 2001;7:613-619.
5. Georges GE, Storb R, Thompson JD, et al. Adoptive immu-
notherapy in canine mixed chimeras after nonmyeloablative
hematopoietic cell transplantation. Blood. 2000;95:3262-3269.
6. Storb R, Weiden PL, Deeg HJ, et al. Rejection of marrow from
DLA-identical canine littermates given transfusions before
grafting: antigens involved are expressed on leukocytes and skin
epithelial cells but not on platelets and red blood cells. Blood.
1979;54:477-484.
7. Storb R, Yu C, Barnett T, et al. Stable mixed hematopoietic
chimerism in dog leukocyte antigen-identical littermate dogs
given lymph node irradiation before and pharmacologic immu-
nosuppression after marrow transplantation. Blood. 1999;94:
1131-1136.
8. Storb R, Sale G, Barnett T, Yu C, Zellmer E, Little M-T.
Transient mixed hematopoietic chimerism in dogs given thy-
mic irradiation before and pharmacologic immunosuppression
after marrow transplantation. Blood. 2001;97:2915-2916.
9. Xun C-Q, Little M-T, Zellmer E, et al. What role for FTY720,
a novel immunosuppressive agent, in canine nonmyeloablative
hematopoietic stem cell transplantation? Transplantation. 2002;
73:310-313.
10. Kalhs P, White JS, Gervassi A, Storb R, Bean MA. In vitro
recall of proliferative and cytolytic responses to minor histo-
compatibility antigens by dendritic cell enriched canine periph-
eral blood mononuclear cells. Transplantation. 1995;59:112-
118.
11. Ha¨gglund HG, McSweeney PA, Mathioudakis G, et al. Ex vivo
expansion of canine dendritic cells from CD34 bone marrow
progenitor cells. Transplantation. 2000;70:1437-1442.
12. Wagner JL, Burnett RC, DeRose SA, Francisco LV, Storb R,
Ostrander EA. Histocompatibility testing of dog families with
highly polymorphic microsatellite markers. Transplantation.
1996;62:876-877.
13. Wagner JL, Burnett RC, Works JD, Storb R. Molecular anal-
ysis of DLA-DRBB1 polymorphism. Tissue Antigens. 1996;48:
554-561.
14. Ladiges WC, Storb R, Graham T, Thomas ED. Experimental
techniques used to study the immune system of dogs and other
large animals. In: Gay WI, Heavener JE, eds.Methods of Animal
Experimentation. New York, NY: Academic Press; 1989:103-
133.
15. Yu C, Ostrander E, Bryant E, Burnett R, Storb R. Use of (CA)n
polymorphisms to determine the origin of blood cells after
allogeneic canine marrow grafting. Transplantation. 1994;58:
701-706.
16. Yunusov MY, Georges GE, Storb R, et al. FLT3 ligand pro-
motes engraftment of allogeneic hematopoietic stem cells with-
out signiﬁcant graft-versus-host disease. Transplantation (in
press).
17. Bruno B, Nash RA, Wallace PM, et al. CD34 selected bone
marrow grafts are radioprotective and establish mixed chimer-
ism in dogs given high dose total body irradiation. Transplan-
tation. 1999;68:338-344.
18. McSweeney PA, Rouleau KA, Wallace PM, et al. Character-
ization of monoclonal antibodies that recognize canine CD34.
Blood. 1998;91:1977-1986.
19. Georges GE, Storb R, Brunvand MW, et al. Canine T cells
transduced with a herpes simplex virus thymidine kinase gene:
a model to study effects on engraftment and control of graft-
versus-host disease. Transplantation. 1998;66:540-544.
20. Holmberg LA, Seidel K, Leisenring W, Torok-Storb B. Aplas-
tic anemia: analysis of stromal cell function in long-term mar-
row cultures. Blood. 1994;84:3685-3690.
21. Torok-Storb B, Simmons P, Barge A, Kaushansky K, Migliac-
cio AR, Johnson G. Mechanisms of marrow graft failure. In:
Sachs L, Abraham NG, Wiedermann CJ, Levine AS, Kon-
walinka G, eds. Molecular Biology of Haematopoiesis. Andover,
NH: Intercept; 1990:589-596.
22. Accolla RS, Birnbaum D, Pierres M. The importance of cross-
reactions between species: mouse allo-anti-Ia monoclonal anti-
bodies as a powerful tool to deﬁne human Ia subsets. Hum
Immunol. 1983;8:75-82.
23. Torok-Storb B, Holmberg L, Mielcarek M. Mechanisms of
poor marrow function and late graft failure. In: Atkinson K, ed.
Clinical Bone Marrow and Blood Stem Cell Transplantation. Cam-
bridge, UK: Cambridge University Press; 2000:67-73.
24. Kuhr CS, Allen MD, Junghanss C, et al. Tolerance to vascu-
larized kidney grafts in canine mixed hematopoietic chimeras.
Transplantation. 2002;73:1487-1493.
25. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete
remission of accelerated phase chronic myeloid leukemia by
treatment with leukemia-reactive cytotoxic T lymphocytes.
Blood. 1999;94:1201-1208.
26. Warren EH, Kelly DM, Brown ML, Koo KK, Xuereb SM,
Riddell SR. Adoptive GVL therapy targeting minor histocom-
patibility antigens for the treatment of posttransplant leukemic
relapse-update of the FHCRC experience. Blood. 2002;100(part
1):633a [abstr. 2493].
27. Roopenian D. Lessons from H3, a model autosomal mouse
minor histocompatibility locus. In: Roopenian D, Simpson E,
eds. Minor Histocompatibility Antigens: From the Laboratory to the
Clinic. Georgetown, TX: Landes Bioscience; 2000:1-14.
28. Georges GE, Storb R, Bruno B, et al. Engraftment of DLA-
haploidentical marrow with ex vivo expanded, retrovirally
transduced cytotoxic T lymphocytes. Blood. 2001;98:3447-3455.
G. E. Georges et al.
242
